PDB50 DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.932
https://www.valueinhealthjournal.com/article/S1098-3015(19)33310-8/fulltext
Section Title :
Section Order :
10824
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33310-8&doi=10.1016/j.jval.2019.09.932